ATE224396T1 - N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine - Google Patents

N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine

Info

Publication number
ATE224396T1
ATE224396T1 AT95924657T AT95924657T ATE224396T1 AT E224396 T1 ATE224396 T1 AT E224396T1 AT 95924657 T AT95924657 T AT 95924657T AT 95924657 T AT95924657 T AT 95924657T AT E224396 T1 ATE224396 T1 AT E224396T1
Authority
AT
Austria
Prior art keywords
indole
purine
substituted
pyrimidine
derivatives
Prior art date
Application number
AT95924657T
Other languages
English (en)
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Ronald J Uhing
Henry Wong
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE224396T1 publication Critical patent/ATE224396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT95924657T 1994-06-22 1995-06-21 N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine ATE224396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,039 US5643893A (en) 1994-06-22 1994-06-22 N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
PCT/US1995/007936 WO1995035300A1 (en) 1994-06-22 1995-06-21 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines

Publications (1)

Publication Number Publication Date
ATE224396T1 true ATE224396T1 (de) 2002-10-15

Family

ID=23004300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924657T ATE224396T1 (de) 1994-06-22 1995-06-21 N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine

Country Status (16)

Country Link
US (1) US5643893A (de)
EP (1) EP0767793B1 (de)
JP (1) JP3805789B2 (de)
KR (1) KR970703975A (de)
AT (1) ATE224396T1 (de)
AU (1) AU2907795A (de)
CA (1) CA2193644A1 (de)
DE (1) DE69528267T2 (de)
DK (1) DK0767793T3 (de)
ES (1) ES2183877T3 (de)
FI (1) FI965141A7 (de)
HU (1) HUT76298A (de)
NO (1) NO965521L (de)
NZ (1) NZ289286A (de)
PT (1) PT767793E (de)
WO (1) WO1995035300A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310070B1 (en) * 1997-07-15 2001-10-30 Japan Energy Corporation Purine derivatives and medicinal use thereof
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
WO2002056832A2 (en) * 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004071383A2 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MY146066A (en) * 2004-07-01 2012-06-29 Microlin L C Device employing gas generating cell for facilitating controlled release of fluid into ambient environment
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20080319044A1 (en) * 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
EP1812451A4 (de) * 2004-11-01 2009-10-21 Nuada Llc Verbindungen und verfahren zu deren anwendung
US20090264384A1 (en) * 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2279291B1 (de) * 2008-04-09 2019-07-03 Cornell University Coferone und verfahren zu deren herstellung und anwendung
AU2009233711B2 (en) * 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2485678A4 (de) 2009-10-07 2013-04-03 Univ Cornell Coferone sowie verfahren zu ihrer herstellung und verwendung
BR112012019120A2 (pt) 2010-02-03 2016-06-28 Infinity Pharmaceuticais Inc forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
EP2647639A1 (de) * 2012-04-06 2013-10-09 LEK Pharmaceuticals d.d. ß-boration Alken- und Alkyn-Zwischenstoffen
EP3913068B1 (de) 2015-10-12 2023-08-02 Advanced Cell Diagnostics, Inc. In-situ-detektion von nukleotidvarianten bei proben mit hohem rauschen sowie zugehörige zusammensetzungen und verfahren
JP2025531789A (ja) 2022-09-07 2025-09-25 エムディーエックス マネージメント エルエルシー がん治療のためのｓｈｐ－１阻害剤
CN120916767A (zh) 2022-11-02 2025-11-07 Mdx管理有限责任公司 用于治疗癌症的酪氨酸激酶抑制剂和促炎剂的组合
EP4680215A1 (de) 2023-03-17 2026-01-21 MDX Management LLC Zusammensetzungen und verfahren zur linderung von nebenwirkungen von therapien
CN122029273A (zh) 2023-08-16 2026-05-12 Mdx管理有限责任公司 用于激活免疫细胞的组合物和方法
WO2025188921A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Shp-1 inhibitors and activators of t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
JP3805789B2 (ja) 2006-08-09
FI965141A0 (fi) 1996-12-20
NO965521D0 (no) 1996-12-20
WO1995035300A1 (en) 1995-12-28
EP0767793B1 (de) 2002-09-18
DK0767793T3 (da) 2002-10-14
FI965141L (fi) 1996-12-20
AU2907795A (en) 1996-01-15
DE69528267T2 (de) 2003-04-17
NO965521L (no) 1997-02-21
NZ289286A (en) 1998-09-24
DE69528267D1 (de) 2002-10-24
JPH10507739A (ja) 1998-07-28
CA2193644A1 (en) 1995-12-28
EP0767793A1 (de) 1997-04-16
US5643893A (en) 1997-07-01
ES2183877T3 (es) 2003-04-01
HU9603536D0 (en) 1997-02-28
HUT76298A (en) 1997-07-28
FI965141A7 (fi) 1996-12-20
KR970703975A (ko) 1997-08-09
PT767793E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
DE69528267D1 (de) N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine
ATE186545T1 (de) Hydroxyalkylammonium-pyrimidine und purine und nukleosidderivate zur inhibierung entzündlicher cytokine
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
EA199700356A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИНЫ ДЛЯ ИНГИБИРОВАНИЯ ОПОСРЕДОВАННОЙ ПРОТЕИНТИРОЗИНКИНАЗЫ КЛЕТОЧНОЙ ПРОЛИФЕРАЦИИ
EA200201096A1 (ru) СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
NO952398L (no) Pyrrolpyrimidiner som CRF antagonister
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
FI971953A0 (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6-aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
BG100137A (bg) Аналози на сиалил lе горе х като инхибитори на клетъчната адхезия
ATE242245T1 (de) Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
DK0988301T3 (da) Imidazolylcykliske acetaler
MX9702488A (es) Compuestos de purina y guanina como inhibidores de pnp.
SE9702773D0 (sv) Novel compounds
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ATE246184T1 (de) Chinoline und deren therapeutische verwendung
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
EA200200558A1 (ru) 2-( 1h-индол-3-ил)-2-оксоацетамиды, обладающие противоопухолевой активностью
ATE209187T1 (de) Fluorinierte 2-nitroimidazole analoge zur detektion von hypoxischen tumorzellen
DK1173439T3 (da) Halogenalkoxy-imidazonaphthyridiner
ATE85614T1 (de) Psychotropische bizyklische imide.
DE60015945D1 (en) 2-hydroxy methylcyclopropylidenmethylpurine als antivirale wirkstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0767793

Country of ref document: EP

REN Ceased due to non-payment of the annual fee